Valiant Laboratories Ltd Quarterly Results, Profit & Loss, Balance Sheet (VALIANTLAB) | Stocksigma

Valiant Laboratories Ltd (VALIANTLAB) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow

Valiant Laboratories Ltd reported sales of ₹116.77 Cr, operating profit of ₹5.18 Cr (OPM 4.44%) and net profit of ₹0.41 Cr for the quarter ended Sep 2026. Figures in ₹ crore, consolidated where available.

VALIANTLAB quarterly results (₹ Cr)
Metric	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Sales	35.23	57.79	46.82	46.2	52.46	91.98	115.29	116.77
Expenses	34.61	53.97	44.43	46.12	53.35	87.17	86.03	111.59
Operating Profit	0.62	3.82	2.39	0.08	-0.89	4.81	29.26	5.18
OPM	1.76%	6.61%	5.1%	0.17%	-1.7%	5.23%	25.38%	4.44%
Other Income	1.58	-2.31	0.66	0.87	0.63	0.17	0.86	0.11
Interest	0.06	0.05	0.07	0.14	0.68	1.01	1.07	0.96
Depreciation	0.52	0.52	0.53	0.53	2.05	2.93	2.86	3.66
Profit before tax	1.62	0.94	2.45	0.28	-2.99	1.04	26.19	0.67
Tax	-44.44%	25.53%	25.71%	25%	136.12%	-68.27%	19.43%	37.31%
Net Profit	2.35	0.7	1.82	0.2	-7.06	1.76	21.1	0.41
EPS in Rs	0.5	0.15	0.39	0.04	-1.3	0.32	3.88	0.08

VALIANTLAB profit & loss, annual (₹ Cr)
Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	334	182	133	237	376
Expenses	299	190	138	231	338
Operating Profit	35	-8	-5	6	38
OPM	11%	-4.6%	-3.5%	2.7%	10%
Other Income	5	10	5	2	2
Interest	0	0	0	2	4
Depreciation	2	2	2	6	12
Profit before tax	38	-1	-2	1	25
Tax	24%	-142%	46%	525%	-
Net Profit	29	0	-2	-3	16
EPS in Rs	8.26	0.07	-0.47	-0.6	2.98
Dividend Payout	0%	0%	0%	0%	-

VALIANTLAB balance sheet (₹ Cr)
Metric	Mar 2023	Mar 2024	Mar 2025	Sep 2025	Mar 2026
Equity Capital	33	43	43	54	54
Reserves	68	193	191	263	257
Borrowings	60	77	122	54	46
Other Liabilities	52	29	45	54	107
Total Liabilities	213	343	401	425	464
Fixed Assets	48	50	48	48	227
CWIP	1	43	156	174	6
Investments	34	38	0	48	26
Other Assets	130	212	197	155	205
Total Assets	213	343	401	425	464

VALIANTLAB cash flows (₹ Cr)
Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	56	2	1	-10
Cash from Investing Activity	-55	-144	-53	7
Cash from Financing Activity	-1	152	45	2
Net Cash Flow	0	10	-7	-1
Free Cash Flow	18	-44	-112	-45
CFO/OP	185%	-11%	25%	-147%
CFO/EBITDAShare of operating profit converting into cash: CFO (before tax) / Operating Profit	185	-11	25	-147

VALIANTLAB ratios
Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	97	92	197	144
Inventory Days	17	22	13	84
Days Payable	62	56	128	175
Cash Conversion Cycle	52	57	82	53
Working Capital Days	70	106	156	116
ROCE	-	-2%	-1%	1%